Related to AstraZeneca, Agendia, and The Netherlands Cancer Institute Team Up to Develop Colorectal Cancer Therapies

• Financial Focus: Monogram Enters Theranostic Market
  
• BioMarket Trends: Pitfalls Undermine Promise of Theranostics
  
• Wall Street BioBeat: Molecular Diagnostics Take Center Stage
  
• BioMarket Trends: Companion Diagnostic Reimbursement
  
• Feature Articles: Finding Promising Protein Biomarkers
  
• Point of View: Innovation Can Prosper in a Regulated Environment
  
• BioMarket Trends: Do Companion Dx Make Economic Sense?
  
• Feature Articles: Molecular Diagnostic Alliances Increasingly the Norm
  
• BioPerspectives: Bring a Friend: Cancer Companion Diagnostics Become Popular
  
• Feature Articles: FDASIA’s Impact on Novel IVDs
  
• Wall Street BioBeat: Companion Dx and Personalized Medicine
  
• BioMarket Trends: Rise of Cell-Based Immunotherapy
  
• Corporate Profiles: Exploiting Folate Pathways to Treat Cancer
  
• BioPerspectives: Personalized Medicine: From Biomarkers to Companion Diagnostics
  
• Corporate Profiles: Softening the Blow from FOLFOX Treatment